The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity

This study explores the long-term effects of dapagliflozin and empagliflozin on CYP8B1 gene expression and a range of metabolic, oxidative, and inflammatory biomarkers in obese patients with Type 2 Diabetes Mellitus (T2DM). Over a 6-month period, participants are assigned to three treatment arms: metformin (control), dapagliflozin, and empagliflozin. The study aims to determine how these medications influence bile acid metabolism, oxidative stress, leptin, GLP-1, IL-10, and IFN-γ, providing insight into the broader metabolic benefits of SGLT2 inhibitors

NCT Number	NCT07120828
Lead Sponsor	Erbil Polytechnic University Collaborators: Kurdistan Higher Council of Medical Specialties
Conditions	Type 2 Diabetes, Obese Diabetics, Obese Patients (BMI ≥ 30 kg/m²)
Enrollment	260 participants
Start Date	2025-07-15
Primary Completion	2025-08-30 (estimated)
Study Completion	2026-03-15 (estimated)
Updated on ClinicalTrials.gov	2026-03-17